GB202304262D0 - Flavonoid compound for use in the treatment of diseases and conditions associated with movement disorders - Google Patents

Flavonoid compound for use in the treatment of diseases and conditions associated with movement disorders

Info

Publication number
GB202304262D0
GB202304262D0 GBGB2304262.5A GB202304262A GB202304262D0 GB 202304262 D0 GB202304262 D0 GB 202304262D0 GB 202304262 A GB202304262 A GB 202304262A GB 202304262 D0 GB202304262 D0 GB 202304262D0
Authority
GB
United Kingdom
Prior art keywords
diseases
treatment
conditions associated
movement disorders
flavonoid compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB2304262.5A
Other versions
GB2619147A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ontrack Therapeutics Ltd
Original Assignee
Ontrack Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ontrack Therapeutics Ltd filed Critical Ontrack Therapeutics Ltd
Publication of GB202304262D0 publication Critical patent/GB202304262D0/en
Priority to PCT/GB2023/051356 priority Critical patent/WO2023227882A1/en
Publication of GB2619147A publication Critical patent/GB2619147A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB2304262.5A 2022-05-24 2023-03-23 Flavonoid compound for use in the treatment of diseases and conditions associated with movement disorders Pending GB2619147A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/GB2023/051356 WO2023227882A1 (en) 2022-05-24 2023-05-24 4-(6-oxo-2-(trifluoromethyl)-3,6-dihydrochromeno[7,8-d]imidazol-8-yl)benzonitril e for the treatment of diseases and conditions associated with movement disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2207557.6A GB202207557D0 (en) 2022-05-24 2022-05-24 Flavonoid compound for use in the treatment of diseases and conditions associated with movement disorders

Publications (2)

Publication Number Publication Date
GB202304262D0 true GB202304262D0 (en) 2023-05-10
GB2619147A GB2619147A (en) 2023-11-29

Family

ID=82220585

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB2207557.6A Ceased GB202207557D0 (en) 2022-05-24 2022-05-24 Flavonoid compound for use in the treatment of diseases and conditions associated with movement disorders
GB2304262.5A Pending GB2619147A (en) 2022-05-24 2023-03-23 Flavonoid compound for use in the treatment of diseases and conditions associated with movement disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB2207557.6A Ceased GB202207557D0 (en) 2022-05-24 2022-05-24 Flavonoid compound for use in the treatment of diseases and conditions associated with movement disorders

Country Status (1)

Country Link
GB (2) GB202207557D0 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4344743A2 (en) * 2018-08-07 2024-04-03 Emory University Heterocyclic flavone derivatives, compositions, and methods related thereto

Also Published As

Publication number Publication date
GB202207557D0 (en) 2022-07-06
GB2619147A (en) 2023-11-29

Similar Documents

Publication Publication Date Title
IL288214A (en) Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders
IL287032A (en) Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes
EP4031152A4 (en) Methods and probiotic compositions for the treatment of metabolic diseases and disorders
EP3583113A4 (en) Use of tgf alpha for the treatment of diseases and disorders
SG11202110174PA (en) Compositions and methods for the treatment of kras associated diseases or disorders
IL289167A (en) 2h-indazole derivatives and their use in the treatment of disease
IL287280A (en) Compounds and methods for the treatment of ocular disorders
EP4054713A4 (en) Compositions and methods for treatment or prevention of skin diseases and disorders with lekti
EP3915985A4 (en) Pyrrolopyridine derivative and use thereof in prevention and treatment of protein kinase-related disease
IL287264A (en) Compounds and methods for the treatment of ocular disorders
IL286268A (en) Pridopidine for use in the treatment of mitochondrial associated diseases and disorders, including symptoms thereof
IL272253A (en) Compositions and methods for treatment of inflammatory conditions and diseases of the skin
EP4010075A4 (en) Methods for the treatment of apoc3-related diseases and disorders
PT3937948T (en) Phytoecdysones and the derivatives thereof for use in the treatment of neuromuscular diseases
GB202304262D0 (en) Flavonoid compound for use in the treatment of diseases and conditions associated with movement disorders
GB202207559D0 (en) Flavonoid compound for use in the treatment of diseases and conditions associated with movement disorders
EP3955914A4 (en) Novel compounds and methods of use treating fructose-related disorders or diseases
IL309317A (en) Treatment of mtres1 related diseases and disorders
TWI799923B (en) Use of thioimidazolidinone drugs in the treatment of covid-19 disease
IL282562A (en) Composition and use for the treatment of parkinson's disease and related disorders
GB202211274D0 (en) Flavonoid compound for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction
GB202207556D0 (en) Flavonoid compound for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction
EP4017496A4 (en) Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases
GB202217454D0 (en) Compounds for use in the treatment of diseases and conditions associated with anxiety and / or mood disorders
GB202217453D0 (en) Compounds for use in the treatment of diseases and conditions associated with inflammation or autoimmunity